Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

Coronary computed tomography angiography is a cheaper, less-invasive alternative to intravascular ultrasound in pharmaceutical clinical trials
Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA
The Benefits of Coronary CTA in Pharmaceutical Clinical Trials

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

Time July 11, 2023
arrow
NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

July 5, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 05, 2023
arrow
Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on radiotherapies and theranostics readiness at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting.
News | SNMMI
Cardinal Health Highlights Nuctrac Theranostic Module, Theranostics Readiness at SNMMI 2023

June 23, 2023 — Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on ...

Time June 23, 2023
arrow
Therapeutically equivalent and fully substitutable to Kinevac (Sincalide for Injection) formulated, filled and packaged in the United States provides health care facilities with choice and value
News | Contrast Media
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

June 21, 2023 — Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the ...

Time June 21, 2023
arrow
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer
Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
arrow
Planned transition part of NorthStar’s strategy for continued growth and industry leadership in domestic radioisotope production and radiopharmaceutical development to meet needs of patients, pharmaceutical companies and radiopharmacies
News | Radiopharmaceuticals and Tracers
NorthStar Medical Technologies, LLC Appoints Frank Scholz, PhD, as President and Chief Executive Officer

June 19, 2023 — NorthStar Medical Technologies, LLC, a global innovator in the development, production and ...

Time June 19, 2023
arrow
The first patient has been scanned in a Phase I clinical trial for an investigational fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical
News | Radiopharmaceuticals and Tracers
First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

June 15, 2023 — With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare ...

Time June 15, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer
News | Prostate Cancer
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements
News | PET Imaging
GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

April 28, 2023 — GE HealthCare to deliver two Cyclotrons next year, expanding South Africa’s capacity to produce ...

Time April 28, 2023
arrow
NorthStar Medical Radioisotopes has expanded its management team with the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

April 24, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 24, 2023
arrow
NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

April 13, 2023 —NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 13, 2023
arrow
New radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) provides powerhouse combination of capabilities and expertise to advance patient care
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

April 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 03, 2023
arrow
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications
News | PET Imaging
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

March 29, 2023 — Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to ...

Time March 29, 2023
arrow
RYZ101 positioned to be the first approved Actinium-225 radiopharmaceutical therapy for the industry
News | Radiopharmaceuticals and Tracers
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

March 20, 2023 — RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against ...

Time March 20, 2023
arrow
A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients
News | Radiopharmaceuticals and Tracers
Pluvicto Supply Shortage Update: What SNMMI is Doing

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...

Time March 16, 2023
arrow
100-foot crane lifting Rhodotron TTE-300 HE Electron Beam Accelerator at NorthStar Medical Radioisotope's new Ac-225 Production facility in Beloit, Wisconsin (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)

March 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 03, 2023
arrow
Sponsored Content | Videos | Contrast Media
VIDEO: Talking Trends with Bracco: Investing in the Future of Radiology

Bracco Diagnostics and Guerbet recently announced they had formed a strategic, global collaboration for the research ...

Time February 27, 2023
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now